

Serial No.: 09/806,5252  
Filed: March 30, 2001

Please amend claims 2-5 and 10-12 as follows:


- A<sup>1</sup>
2. A method for the diagnosis of first presentation or recurrence of bladder cancer, the method consisting of the detection of a 37Kda fragment of EGFR in a urine sample.  
*whole fragment score 1,80kda total*
3. A method as claimed in claim 2 wherein the presence of the 37Kda EGFR fragment is detected using an antibody.
4. A method as claimed in claim 2 or claim 3 wherein the presence of 37Kda EGFR fragment is detected using antibody Ab4 EGFR available from Oncogene Science, Inc. → *CAI*
5. The use of antibody Ab4 EGFR in a test to detect the presence of 37Kda EGFR fragment in urine as a diagnostic test for bladder cancer.
- 
10. A method for the diagnosis of bladder cancer, and/or prostate cancer and/or urinary infection, the method comprising a test for the presence of a 37Kda fragment of EGFR in a urine sample.
- A<sup>2</sup>
11. *w/d multiple dep. claim*  
(Amended) A method as claimed in any of claims 2 to 4 and 10 in the form of a dip-stick test.
12. The use of antibodies to the 37Kda fragment of EGFR in the diagnosis of urinary infection, bladder cancer and prostate cancer.

The Commissioner is hereby authorized to charge any additional fees, including extension fees, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. A-70409/RFT/461681-17).

Respectfully submitted,

DORSEY & WHITNEY LLP

Date September 16, 2002

  
Richard F. Trecartin, Reg. No. 31,801  
Filed Under 37 CFR 1.24(a)

Four Embarcadero Center, Suite 3400  
San Francisco, California 94111  
Telephone: (415) 781-1989